Potent complement C3a receptor agonists derived from oxazole amino acids: Structure-activity relationships (original) (raw)

Selective Hexapeptide Agonists and Antagonists for Human Complement C3a Receptor

Huy Truong Hoang

Journal of Medicinal Chemistry, 2010

View PDFchevron_right

The versatile functions of complement C3-derived ligands

Bernadett Valent

Immunological Reviews, 2016

View PDFchevron_right

Derivation of ligands for the complement C3a receptor from the C-terminus of C5a

Trent Woodruff

European journal of pharmacology, 2014

View PDFchevron_right

Derivatives of Human Complement Component C3 for Therapeutic Complement Depletion: A Novel Class of Therapeutic Agents

James Newhouse

Advances in Experimental Medicine and Biology, 2008

View PDFchevron_right

Complement receptor 2–mediated targeting of complement inhibitors to sites of complement activation

Stephen Tomlinson

Journal of Clinical Investigation, 2003

View PDFchevron_right

International Union of Pharmacology. LXXXVII. Complement Peptide C5a, C4a, and C3a Receptors

Peter Monk

View PDFchevron_right

Potent cyclic antagonists of the complement C5a receptor on human polymorphonuclear leukocytes. Relationships between structures and activity

Martin Stoermer

Molecular pharmacology, 2004

View PDFchevron_right

Improving Therapeutic Efficacy of a Complement Receptor by Structure-based Affinity Maturation

Wyne Lee

Journal of Biological Chemistry, 2009

View PDFchevron_right

Characterization of Synthetic C3a Analog Peptides on Human Eosinophils in Comparison to the Native Complement Component C3a

Jörg Köhl

The Journal of Immunology, 2000

View PDFchevron_right

Characterization of complement receptors

Rudolf Schopf

Molecular Immunology, 1982

View PDFchevron_right

Receptors for complement components in inflammation

Y. Gabay

Agents and Actions, 1983

View PDFchevron_right

De Novo Peptide Design with C3a Receptor Agonist and Antagonist Activities: Theoretical Predictions and Experimental Validation

Peter Monk

Journal of Medicinal Chemistry, 2012

View PDFchevron_right

COMPLEMENT RECEPTOR IS AN INHIBITOR OF THE COMPLEMENT CASCADE

Victor Nussenzweig

1981

View PDFchevron_right

QSAR of inhibition of classical pathway of complement activation by dicarboxylic acids

Julian Andia-Pravdivy, A. Kaplun, Svetlana Bureeva

Mendeleev Communications, 2005

View PDFchevron_right

Therapeutic control of complement activation at the level of the central component C3

John Lambris

Immunobiology, 2016

View PDFchevron_right

Soluble form of complement C3b/C4b receptor (CR1) results from a proteolytic cleavage in the C-terminal region of CR1 transmembrane domain

Isabelle Hamer

Biochemical Journal, 1998

View PDFchevron_right

Soluble Complement Receptor 1 Therapeutics

sciaccess inc

Journal of Immunological Sciences, 2022

View PDFchevron_right

Complement C2 Receptor Inhibitor Trispanning and the -Chain of C4 Share a Binding Site for Complement C2

Gerhard Krueger

The Journal of Immunology, 2002

View PDFchevron_right

A small-molecule inhibitor of C5 complement protein

Michael Romanowski

Nature Chemical Biology, 2019

View PDFchevron_right

Exploiting a novel conformational switch to control innate immunity mediated by complement protein C3a

David Fairlie

Nature communications, 2017

View PDFchevron_right

Complement C2 receptor inhibitor trispanning: a novel human complement inhibitory receptor

Prof Sigrun Lange - PhD, FRSB, FLS, Professor of Molecular Pathobiology

The Journal of …, 2005

View PDFchevron_right

Complement peptide receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database

A. Cianciulli

IUPHAR/BPS Guide to Pharmacology CITE, 2019

View PDFchevron_right

Recent developments in low molecular weight complement inhibitors

John Lambris

Molecular Immunology, 2009

View PDFchevron_right

The interaction of soluble human complement receptor type 1 (sCR1, BRL55730) with human complement component C4

Edith Sim

Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 1993

View PDFchevron_right

Binding of fluid-phase complement components C3 and C3b to human lymphocytes

Edith Sim

Biochemical Journal, 1981

View PDFchevron_right

Characterization of the interactions of complement receptor 2 with its ligands iC 3 b , C 3 d and EBV glycoprotein gp 350 / 220

John Lambris

2004

View PDFchevron_right

A novel soluble complement receptor 1 fragment with enhanced therapeutic potential

Martin Spycher

Journal of Biological Chemistry, 2021

View PDFchevron_right

Peptide Inhibitor of Complement C1 (PIC1) Rapidly Inhibits Complement Activation after Intravascular Injection in Rats

Waldon Chen, Frank Lattanzio

PLOS ONE, 2015

View PDFchevron_right

Mediation of a non-proteolytic activation of complement component C3 by phospholipid vesicles

John Lambris

Biomaterials, 2014

View PDFchevron_right

Compstatin, a peptide inhibitor of complement, exhibits species-specific binding to complement component C3

John Lambris

Molecular Immunology, 2003

View PDFchevron_right

A new role for complement C3: Regulation of antigen processing through an inhibitory activity

Christian Villiers

Molecular Immunology, 2008

View PDFchevron_right

Alternative pathway of complement activation by stimulated T lymphocytes I. Binding of C3 fragments

Eva Klein, Gabriella Sarmay

European Journal of Immunology, 1987

View PDFchevron_right

Complement Inhibitors Targeting C3, C4, and C5

John Lambris

Therapeutic Interventions in the Complement System, 2000

View PDFchevron_right

Secretion, cleavage and binding of complement component C3 by the human monocytic cell line U937

Christian Villiers

The Biochemical journal, 1989

View PDFchevron_right

Novel monoclonal antibodies against mouse C3 interfering with complement activation: description of fine specificity and applications to various immunoassays

John d. Lambris, József Prechl, Anna Erdei

Molecular Immunology, 2004

View PDFchevron_right